Our broad portfolio offers products that aid in the delivery of medication, protect healthcare workers and patients from cross-infection and injury, manage patient airway and temperature, as well as deliver specialised care in areas of invitro fertilisation, diagnostics and emergency patient transport.
2015 Headline revenue £836m
2015 Operating profit margin 19.8%
We have operations in over 30 countries with manufacturing located in the US, UK, Mexico, Italy, Germany, Czech Republic, and China. We sell to approximately 120 markets and, while the US continues to be our largest single market with over 50% of sales, we continue to build our presence in developing markets.
Approximately three-quarters of our end user customers are hospitals with the remainder comprising the alternate care market, such as homecare, clinics, and other surgery centres, as well as OEM relationships. We have a direct sales presence in over 20 countries and distribution arrangements in approximately 100 others.
The competitive landscape for Smiths Medical is complex, as we compete with different companies across our business units. Major competitors include Medtronic (Covidien), Teleflex, B Braun, Becton Dickinson (CareFusion), Terumo, C R Bard, 3M, Edwards Lifesciences, and Pfizer (Hospira). We often compete with a portion of a major competitor’s medical device business, as well as single product line companies as they enter a particular market segment. In developing markets, we compete with both large multinational companies and smaller domestic players.
We engage with suppliers to drive product innovation, value engineering and a commitment to quality. We work continuously with our supplier base to reduce product and supply chain costs, improve delivery performance and ensure supply continuity plans. The majority of our direct spending is on resins, plastic injection mouldings and electronics.